Page last updated: 2024-11-02

pioglitazone and Sclerosis, Systemic

pioglitazone has been researched along with Sclerosis, Systemic in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antonelli, A1
Ferri, C1
Ferrari, SM1
Colaci, M1
Ruffilli, I1
Sebastiani, M1
Fallahi, P1

Other Studies

1 other study available for pioglitazone and Sclerosis, Systemic

ArticleYear
Peroxisome proliferator-activated receptor γ agonists reduce cell proliferation and viability and increase apoptosis in systemic sclerosis fibroblasts.
    The British journal of dermatology, 2013, Volume: 168, Issue:1

    Topics: Adult; Aged; Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Female; Fibroblasts; Hum

2013